Dr. Anil Diwan is President & Exec. Chairman of NanoViricides, Inc. He began working in nanomedicines ca. 1992. He invented the "TheraCour®" targeted drug delivery technologies that form the basis of the nanoviricides® platform, at AllExcel, Inc., a private company he founded. Dr. Diwan co-founded NanoViricides, Inc. (NNVC) which became public through a reverse shell merger in 2005, and he led its up-listing to NYSE-Amer. exchange in Sep. 2013. He helped raise or raised over $65MM. Dr. Diwan played a key role in developing a flexible, multi-product, cGMP-capable, R&D and Drug Product Manufacturing Facility that was purchased at cost by NanoViricides, Inc. He is intimately involved in drug development activities from design to drug product. Dr. Diwan performed post-doctoral research in Virology at Univ. of Connecticut, Storrs, & in Biomedical Engg. at Univ. of Wisconsin, Madison. He holds a PhD in (Bio)Chem. Engg. from Rice Univ., Houston, TX, and a BTech (Chem Engg.) from IIT Bombay.